- About MHRP
- International Network
- Prevention, Care & Treatment
- News & Publications
An Army-sponsored phase III clinical trial (RV144) involving more than 16,000 adult volunteers in Thailand showed that an investigational HIV vaccine regimen was safe and modestly effective in preventing HIV infection.
RV217: A multi-site research study on acute HIV infections
RV254: An early HIV infection study in Thailand
RV262: Phase I study to evaluate a combination DNA prime/MVA vector boost vaccine regimen
RV305: Immunogenicity study evaluating extended boosting regimens using the same vaccine components used in RV144
RV329: African Cohort Study
The findings, published in the journal AIDS, highlight the complexity of the outbreak and may have implications on future HIV vaccine development in the region.
The 2015 International AIDS Society Conference will be held in Vancouver, Canada July 19- 22. Read on to learn more about MHRP oral and poster presentations and well as special sessions hosted by MHRP researchers.
New findings from an RV144 follow-on study published today in Science Translational Magazine provide key insights into the role that host-genetics played in protecting against HIV-1 infection during the landmark “Thai Study.”
Researchers believe findings from a new MHRP study in humanized DRAG mice will provide a new pre-clinical model to understand the early events in mucosal HIV infection and help to evaluate candidate HIV vaccines.
While it may still take another decade to have a globally effective HIV Vaccine, recent advancements give powerful reason for optimism.
Survivors of the 2007-08 Bundibugyo ebolavirus (BDBV) outbreak in Uganda experienced negative health effects that persisted more than two years after the outbreak claimed 39 lives, according to findings from an MHRP study published in the Lancet ID today.
In a new paper, published in the journal BBA Biomembranes, MHRP researcher and liposome pioneer Dr. Carl Alving and his team deconstruct the underlying science behind the physical structure of the world’s most potent vaccine adjuvant.
Findings from a WRAIR/NIAID led Ebola vaccine clinical trail were published in the New England Journal of Medicine today, highlighting that the vaccine candidate is safe and elicits a robust immune response.
The Role of Research Nurses in HIV Research
Nurses play an integral role on the research team of HIV studies and vaccine clinical trials. Read more about two hard-working nurses who are helping MHRP in the quest to find an end to AIDS.
Video: Early HIV Infection Study Offers Insight Into the Initial Stages of HIV Infection
MHRP researchers and Thai collaborators are leading the way in acute infection studies. One study, called RV254/SEARCH 010 is providing knowledge about the earliest HIV events that may provide clues to developing an effective HIV vaccine or even help identify ways to achieve a functional cure.